Hyperfine, Inc.

NASDAQ:HYPR

Medical - Devices

Healthcare
$0.56 +15.65%

+$0.22 today

Market cap
$51.10M
Beta
1.38
P/E (TTM)
-4.5
EPS (TTM)
-$0.36
52W Low $0.66High $2.22

Volume 1.16M

Average 0.60M

HYPR EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Hyperfine, Inc.NASDAQ: HYPR

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$8.27M, compared with -$9.19M a year earlier. Trailing-twelve-month EBITDA was -$33.15M.

Context

  • EBITDA amounted to 246.1% of revenue in FY2025, down 62.0 pp from a year earlier.
  • EBITDA grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 3 analysts of -$27.89M (+16.4%) for the fiscal year ending Dec 2026, a pace similar to FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$8.27M-58.5% QoQ
Last fiscal yearDec 2025
-$33.37M+16.0% YoY
LTMMar 2026
-$33.15M+15.7% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.0%+2.1%-7.9 pp
1 year+16.0%+16.4%+0.5 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(33.37M) USD
Year-over-year change
+16.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How HYPR compares with its peers on the latest reported figures

  • HYPR's LTM Mar 2026 EBITDA of -$33.15M is the 3rd highest of the 7 companies compared; the peer median is -$42.97M.
  • Its year-over-year change of +15.7% is the 2nd highest of 7, against a peer median of -10.9%.
  • EBITDA amounts to 216.2% of revenue for HYPR, versus a peer median of 53.3%.
HYPR Competitors Peer median
EBITDA for HYPR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FONRFONAR CorporationLTM Mar 2026$15.91M -15.8%-12.5%15.1%
VANIVivani Medical, Inc.LTM Mar 2026-$26.64M -14.1%——
HYPRHyperfine, Inc.LTM Mar 2026-$33.15M +15.7%—216.2%
RCELAVITA Medical, Inc.LTM Mar 2026-$37.72M +25.1%—52.1%
LUNGPulmonx CorporationLTM Mar 2026-$48.22M +9.4%—54.5%
IMAImageneBio IncLTM Mar 2026-$51.64M -7.8%——
CNTBConnect Biopharma Holdings LimitedFY2025-$54.58M -270.2%—85279.7%
Peer median (excluding HYPR) -$42.97M-10.9%-12.5%53.3%

Competitors are the stored peer set for HYPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.5M6.81M11.03M12.89M13.56M
Cost of Revenue2.66M5.91M6.28M7M6.81M
Gross Profit(1.17M)907K4.76M5.89M6.75M
Gross Margin-78.0%13.3%43.1%45.7%49.8%
Research & Development25.84M28.16M22.49M22.5M17.45M
Selling, General & Admin37.86M46.63M30.38M26.62M26.39M
Operating Expenses63.7M74.78M52.87M49.12M43.84M
Depreciation & Amortization726K1.02M1.05M1.01M2.2M
EBITDA(64.13M)(72.15M)(43.18M)(39.71M)(33.37M)
EBITDA Margin-4286.4%-1058.8%-391.4%-308.1%-246.1%
Operating Income(64.87M)(73.87M)(48.12M)(43.22M)(37.09M)
Operating Margin-4336.1%-1084.2%-436.1%-335.3%-273.4%
Interest Income18K761K3.84M2.49M1.02M
Interest Expense00000
Other Income / Expenses17K710K3.88M2.5M1.51M
Income Before Tax(64.85M)(73.16M)(44.24M)(40.72M)(35.57M)
Pre-Tax Margin-4335.0%-1073.7%-401.0%-315.9%-262.3%
Income Tax Expense00000
Net Income(64.83M)(73.16M)(44.24M)(40.72M)(35.57M)
Net Margin-4333.8%-1073.7%-401.0%-315.9%-262.3%
EPS (Basic)(0.92)(1.04)(0.62)(0.56)(0.43)
EPS (Diluted)(0.92)(1.04)(0.62)(0.56)(0.43)
Weighted Avg Shares70.33M70.45M71.32M72.41M94.2M
Weighted Avg Shares (Diluted)70.33M70.45M71.32M72.41M94.2M

Hyperfine, Inc.

NASDAQ:HYPR

Intrinsic Alpha fair value

Locked

Current Price

$0.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.